Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  fluorouracil
Find trials that include:  Any drugs shown
Results 1-25 of 100 for your search:
Start Over
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1048, NCI-2012-00234, CDR0000715321, NCCTG-N1048, PN1048_A11PAMDREVW01, NCT01515787
Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-HN001, NCI-2014-00635, NCT02179164, RTOG-1305, NCT02135042
Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, NCT02265692, PAHEP0731_A08PAMDREVW01, NCT00980460
Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 80702, NCI-2011-02050, CALGB/SWOG 80702, CALGB-SWOG C80702, CDR0000675693, NCT01150045
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: YO28322, NCI-2013-01693, 2012-001402-23, NCT01662869
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NLG0505, NCI-2013-01044, 1210-1195, NCT01836432
Combination Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Locally Advanced Pancreatic Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: PANC0015, NCI-2013-01658, 5136, NCT01926197
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: EP-GF-301, NCI-2013-02181, NCT01954992
Imiquimod, Fluorouracil, or Observation in Treating Patients With High-Grade Anal Squamous Skin Lesions Who Are HIV-Positive
Phase: Phase III
Type: Treatment
Age: 27 and over
Trial IDs: AMC-088, NCI-2013-02288, NCT02059499
Topical or Ablative Treatment in Preventing Anal Cancer in Patients with HIV and Anal High-Grade Squamous Intraepithelial Lesions
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Age: 35 and over
Trial IDs: AMC-A01, NCI-2014-00636, NCT02135419
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
Veliparib and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-608, NCI-2013-00656, NCT01489865
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BrUOG 276, NCI-2014-00505, NCT01671488
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
S1313, Combination Chemotherapy with or without PEGPH20 in Treating Patients with Newly Diagnosed Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1313, NCI-2013-01776, NCT01959139
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: PaTK02, NCI-2015-00859, NCT02446093
Radiation Therapy and Cisplatin or Mitomycin and Fluorouracil in Treating Patients with Non-Muscle Invasive Stage I Bladder Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0926, NCI-2011-01974, 13-C-0175, CDR0000654727, PRTOG-0926_A05PAMDREVW01, NCT00981656
A Study in Advanced Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13420, NCI-2012-01213, I4E-MC-JXBB, NCT01063075
Start Over